ImageneBio, Inc. - Common Stock IMA 深 滬
等待開盤 12-12 09:30:00 美东时间
6.47
+0.040
+0.62%
華盛通- 最 高6.6095
- 今 開6.6095
- 成交量 4.41万股
- 最 低 6.37
- 昨 收 6.43
- 總市值 7234.56万
- 52周最高 23.28
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.19
- 委 比 -33.33%
- 總股本 1118.17万
- 歷史最高 451.32
- 量 比 0.60
- 振 幅 3.72%
- 歷史最低 6.37
- 每 手 1
- 風險率 4.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
Wedbush Assumes ImageneBio at Underperform, Announces Price Target of $2
Wedbush analyst Martin Fan assumes ImageneBio (NASDAQ:IMA) with a Underperform rating and announces Price Target of $2.
11-25 22:03
ImageneBio Announces It Intends To Submit Protocol Amendment For Phase 2b ADAPTIVE Study To Expand Number, Exposure Range Of Dosing Regiments, Optimize Feasibility Of Study
ImageneBio, Inc. (Nasdaq: IMA, "Imagene," or the "Company"), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an
11-12 20:18
ImageneBio Q3 EPS $(2.91) Misses $(1.28) Estimate
ImageneBio (NASDAQ:IMA) reported quarterly losses of $(2.91) per share which missed the analyst consensus estimate of $(1.28) by 127.34 percent. This is a 12.79 percent decrease over losses of $(2.58) per share from the
11-12 20:17
沙特卫生部及投资部携易达资本锁定四大领域15亿元总投资，助力中国医疗产业出海
在本届国际医疗健康展上，易达资本联合四家产业公司，与沙特卫生部、沙特投资部共同签署了总额约2.14亿美元（约15亿人民币）的战略合作协议，将围绕血液透析、康复医学、辅助生殖与体检诊断四大方向推动项目落地。
10-29 16:09
天融信DLP再获Gartner推荐
近日，Gartner®发布2025年数据防泄漏供应商清单报告，天融信数据防泄漏（DLP）相关产品再度入选，涵盖网络DLP、终端DLP、邮件DLP、云DLP、数据...
10-28 10:39
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
Leerink Partners Initiates Coverage On ImageneBio with Outperform Rating, Announces Price Target of $30
Leerink Partners analyst David Risinger initiates coverage on ImageneBio (NASDAQ:IMA) with a Outperform rating and announces Price Target of $30.
10-24 18:36
MERRELL AND GRAMICCI UNITE TO REIMAGINE AN OUTDOOR ICON
The Moab 2 Siren x Gramicci Celebrates Movement, Heritage, and A New Generation of Exploration ROCKFORD, Mich., Oct. 23, 2025 /PRNewswire/ -- Merrell, the global leader in hiking and outdoor...
10-23 21:00
